PLoS ONE (Jan 2012)

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.

  • Jeffrey J Wallin,
  • Jane Guan,
  • Kyle A Edgar,
  • Wei Zhou,
  • Ross Francis,
  • Anthony C Torres,
  • Peter M Haverty,
  • Jeffrey Eastham-Anderson,
  • Sabrina Arena,
  • Alberto Bardelli,
  • Sue Griffin,
  • John E Goodall,
  • Kyla M Grimshaw,
  • Klaus P Hoeflich,
  • Christopher Torrance,
  • Marcia Belvin,
  • Lori S Friedman

DOI
https://doi.org/10.1371/journal.pone.0036402
Journal volume & issue
Vol. 7, no. 5
p. e36402

Abstract

Read online

The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant context, an activating PIK3CA mutation (H1047R) was knocked-in to an endogenous allele of the MCF10A non-tumorigenic human breast epithelial cell line. Introduction of an endogenously mutated PIK3CA allele resulted in a marked epithelial-mesenchymal transition (EMT) and invasive phenotype, compared to isogenic wild-type cells. The invasive phenotype was linked to enhanced PIP(3) production via a S6K-IRS positive feedback mechanism. Moreover, potent and selective inhibitors of PI3K were highly effective in reversing this phenotype, which is optimally revealed in 3-dimensional cell culture. In contrast, inhibition of Akt or mTOR exacerbated the invasive phenotype. Our results suggest that invasion is a core phenotype mediated by increased PTEN/PI3K pathway activity and that therapeutic agents targeting different nodes of the PI3K pathway may have dramatic differences in their ability to reverse or promote cancer metastasis.